These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 7867173)

  • 1. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets.
    Alevriadou BR; Moake JL; Turner NA; Ruggeri ZM; Folie BJ; Phillips MD; Schreiber AB; Hrinda ME; McIntire LV
    Blood; 1993 Mar; 81(5):1263-76. PubMed ID: 8443388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
    Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
    Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
    Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys.
    Rote WE; Nedelman MA; Mu DX; Manley PJ; Weisman H; Cunningham MR; Lucchesi BR
    Stroke; 1994 Jun; 25(6):1223-32; discussion 1233. PubMed ID: 8202985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS; Anderson K; Weisman HF
    Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
    Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ; Califf RM; Aguirre FV; Anderson K; Sigmon KN; Weisman HF; Topol EJ
    Am J Cardiol; 1995 Mar; 75(8):559-62. PubMed ID: 7887377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
    Liem TK; Teel R; Shukla S; Silver D
    J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.